Trial Profile

A randomized, open-label, multicenter, phase 2 trial assessing the efficacy and safety of apatinib combined with docetaxel and platinum as neoadjuvant treatment for triple-negative/HER2-positive breast cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Jan 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivoceranib (Primary) ; Carboplatin; Cisplatin; Docetaxel; Lobaplatin; Paclitaxel; Trastuzumab
Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
Focus Therapeutic Use

11 Dec 2020 Primary endpoint has been met. (pathological complete response (pCR))
11 Dec 2020 Results presented at the 43rd Annual San Antonio Breast Cancer Symposium
20 Jan 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com